An investigation for investors in Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares over potential securities laws violations by Eleven Biotherapeutics Inc was announced and NASDAQ:EBIO stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/09/2016 -- An investigation for shareholders in Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares over potential securities laws violations by Eleven Biotherapeutics Inc was announced.
Investors who purchased shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Eleven Biotherapeutics Inc (NASDAQ:EBIO) concerning whether a series of statements by Eleven Biotherapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 18, 2015, Eleven Biotherapeutics Inc (NASDAQ:EBIO) announced results from the OASIS study, the company's first pivotal Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease. Eleven Biotherapeutics Inc said that in this study, EBI-005 did not meet either of these two co-primary endpoints and that there was no statistically significant difference between the EBI-005 treated group and the vehicle control group on the co-primary endpoints or any secondary endpoints.
On January 15, 2016, Eleven Biotherapeutics announced results from the Phase 3 clinical trial of its lead drug candidate, isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis. In this trial, there were no statistically significant differences between the isunakinra treated group and the vehicle control group on the primary endpoint of ocular itching or on any secondary endpoints.
Shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) declined from $$2.34 per share on January 15, 2016 to as low as $0.37 per share on January 21, 2016.
Those who purchased shares of Eleven Biotherapeutics Inc (NASDAQ:EBIO), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com